

Title (en)
USE OF 17-KETOSTEROIDS FOR THE TREATMENT OF MALARIA AND TRYPANOSOMIASIS

Title (de)
VERWENDUNG VON 17-KETOSTEROIDEN ZUR BEHANDLUNG VON MALARIA UND TRYPANOSOMIASIS

Title (fr)
UTILISATION DE COMPOSES 17-CETOSTEROIDES ET DE LEURS DERIVES, METABOLITES ET PRECURSEURS POUR LE TRAITEMENT DU PALUDISME ET LE TRAITEMENT DE LA TRYPANOSIOMASE AFRICAINE OU AMERICAINE

Publication
EP 1135138 A2 20010926 (EN)

Application
EP 99960591 A 19991124

Priority

- US 9928079 W 19991124
- US 10992398 P 19981124
- US 12408799 P 19990311
- US 12605699 P 19990323

Abstract (en)
[origin: WO0032201A2] The invention provides the use of 17-ketosteroid compounds, as well as derivatives, metabolites and precursors of such compounds, and pharmaceutically acceptable salts of any of these compounds, collectively defined herein as the "compounds of the present invention", in the treatment of malaria, African Trypanosomiasis and American Trypanosomiasis, or to ameliorate or reduce one or more symptoms associated with a Plasmodium or Trypanosoma infection. The present invention is further directed to the use of such compounds in the treatment or prevention of one or more kind of parasites and/or one or more diseases caused by such parasites, against one or more kind of Mycoplasma and/or one or more diseases caused by such Mycoplasmas and/or against one or more of the following indications or infections: (a) hairy Leukoplakia, (b) oral candidosis, (c) mouth ulcerations-aphthous/herpetic/bacterial, (d) fungal candida, (e) human papilloma virus, (f) molluscum contagiosum, (g) squamous oral carcinoma, (h) Kaposi's sarcoma oral lesions, (i) periodontitis, (j) necrotizing gingivitis, (k) orafacial herpes zoster, and (l) rotaviruses, as well as all other indications and infections. The compounds of the present invention may also be used to ameliorate or reduce one or more symptoms associated with any infection or condition disclosed herein.

IPC 1-7
A61K 31/56; A61P 33/02; A61P 33/06

IPC 8 full level
A61K 31/353 (2006.01); **A61K 31/357** (2006.01); **A61K 31/56** (2006.01); **A61K 31/565** (2006.01); **A61K 31/566** (2006.01); **A61P 31/00** (2006.01); **A61P 33/00** (2006.01); **A61P 33/02** (2006.01); **A61P 33/06** (2006.01); **C07J 1/00** (2006.01); **C07J 3/00** (2006.01)

CPC (source: EP KR)
A61K 31/56 (2013.01 - EP KR); **A61K 31/565** (2013.01 - EP); **A61K 31/568** (2013.01 - EP); **A61K 31/5685** (2013.01 - EP); **A61P 31/00** (2017.12 - EP); **A61P 33/00** (2017.12 - EP); **A61P 33/02** (2017.12 - EP); **A61P 33/06** (2017.12 - EP); **C07J 1/0011** (2013.01 - EP); **C07J 3/005** (2013.01 - EP); **Y02A 50/30** (2017.12 - EP); **Y02P 20/55** (2015.11 - EP)

Citation (search report)
See references of WO 0032201A2

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 0032201 A2 20000608; WO 0032201 A3 20001221; AP 1584 A 20060301; AP 2001002182 A0 20010630; AU 1745300 A 20000619; AU 2004237812 A1 20050113; AU 2004237812 B2 20071129; AU 776853 B2 20040923; BR 9915623 A 20010814; CA 2356539 A1 20000608; CN 1348373 A 20020508; EP 1135138 A2 20010926; HK 1043319 A1 20020913; IL 142941 A0 20020421; JP 2002531407 A 20020924; KR 20010101073 A 20011114; KR 20070004149 A 20070105; NZ 511720 A 20021220; OA 11715 A 20050314

DOCDB simple family (application)
US 9928079 W 19991124; AP 2001002182 A 19991124; AU 1745300 A 19991124; AU 2004237812 A 20041208; BR 9915623 A 19991124; CA 2356539 A 19991124; CN 99813696 A 19991124; EP 99960591 A 19991124; HK 02105184 A 20020712; IL 14294199 A 19991124; JP 2000584896 A 19991124; KR 20017006523 A 20010524; KR 20067026568 A 20061215; NZ 51172099 A 19991124; OA 1200100127 A 19991124